Increasing Embryonic Morphogen Nodal Expression Suggests Malignant Transformation in Colorectal Lesions and as a Potential Marker for CMS4 Subtype of Colorectal Cancer

Xiaopai Wang¹,²†, Shousheng Liu³†, Huijiao Cao³†, Xiubo Li², Yuming Rong³, Guorong Liu², Hong Du² and Hong Shen¹*

¹Department of Pathology, School of Basic Medical Sciences, Southern Medical University, Guangzhou, China, ²Department of Pathology, Guangzhou First People’s Hospital, School of Medicine, South China University of Technology, Guangzhou, China, ³Department of General Medicine, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China

Nodal, an embryonic morphogen in TGF-β family, is related with tumorigenicity and progression in various tumors including colorectal cancer (CRC). However, the difference of Nodal expression between CRC and colorectal polyps has not yet been investigated. Besides, whether Nodal can be used as a marker for consensus molecular subtype classification-4 (CMS4) of CRC is also worth studying. We analyzed Nodal expression in patients of CRC (161), high-grade intraepithelial neoplasia (HGIN, 28) and five types of colorectal polyps (116). The Nodal expression difference among groups and the association between Nodal expression and clinicopathological features were analyzed. Two categories logistic regression model was used to predict the odds ratio (OR) of risk factors for high tumor-stroma percentage (TSP), and ROC curve was used to assess the diagnostic value of Nodal in predicting high TSP in CRC. We found that Nodal expression was significantly elevated in CRC and HGIN (p < 0.0001). The increased expression of Nodal was related with high TSP, mismatch repair-proficient (pMMR) status, lymph node metastasis and advanced AJCC stage (p < 0.05). Besides, Nodal expression was the only risk factor for high TSP (OR = 6.94; p < 0.001), and ROC curve demonstrated that Nodal expression was able to efficiently distinguish high and low TSP. In conclusion, different expression of Nodal between CRC/HGIN and benign lesions is suggestive of a promoting role for Nodal in colorectal tumor progression. Besides, Nodal might also be used as a potential marker for CMS4 subtype of CRC.

Keywords: Nodal, TGF-β, colorectal cancer, CMS-4, tumor-stroma percentage

INTRODUCTION

As is well-known, colorectal cancer (CRC) is a heterogeneous disease with complicated molecular profile, and the overall survival of CRC patients in advanced stage remains poor, with an approximate 50% overall 5-years survival rate [1]. Vogelstein et al recorded the model of gradual step-wise accumulation of epigenetic and genetic events leading to adenoma and
carcinoma occurrence, and also put forward a new review about the function of ‘driver’ alterations in tumor suppressor genes such as SMAD4 and APC, and oncogenes such as PIK3CA, KRAS and BRAF that screen for advantageous genes and result in CRC progression [1, 2]. More and more researches focus on the molecular changes in CRC tumorigenesis and progression in order to identify novel diagnostic and therapeutic targets for CRC.

The human Nodal gene located on chromosome 10q22, is a member of the Transforming Growth Factor Beta (TGF-β) superfamily and plays a critical role in maintaining pluripotency of human embryonic stem cells (hESCs) and mesodermal differentiation, including epithelial-to-mesenchymal transition (EMT) [3]. Normally, Nodal expression is largely limited to embryonic tissues and not usually expressed in adult tissues [4]. Recently, more and more findings have revealed that Nodal reemerged in a number of tumors such as CRC, melanoma, breast cancer and prostate cancer [5-8]. The initial researches have revealed that Nodal was higher in human colon cancer tissues than that in adjacent noncancerous colon tissues, and Nodal was shown to accelerate self-renewal of human colon cancer stem cells via Smad2/3 signaling pathway [8]. In addition, Nodal and Aldehyde Dehydrogenase-1 can served as prognostic markers for CRC [9]. However, the Nodal expression in colorectal polyps remains unclear. Therefore, we inspected and compared Nodal expression in a wide spectrum of intestinal polyps and CRC using immunohistochemistry (IHC) method.

In 2015, the consensus molecular subtype (CMS) classification of CRC was reported [10], which represented the best description of CRC heterogeneity and might be applied to guide the target therapy in the future. There have been established four CMSs: CMS1 (MSI Immune, 14%) is characterized as exhibiting microsatellite instability (MSI), immune activation and CpG island methylation phenotype (CIMP); CMS2 (Canonical, 37%) is characterized as showing somatic copy number analysis (SCNA), WNT/MYC signaling pathway activation and microsatellite stable (MSS) status; CMS3 (Metabolic, 13%) is characterized as exhibiting evident metabolic dysregulation and KRASt and APC mutations; and CMS4 (Mesenchymal, 23%) is characterized as showing TGF-β activation, stromal invasion and angiogenesis [11]. Particularly, CMS4 usually occurs at advanced stage with poorer prognosis than the other subtypes [12, 13]. The recently reported tumor-stroma percentage (TSP) was used to evaluate the proportions of tumor area infiltrated by stroma, and high TSP (>50%) is an appropriate marker to determine CMS4 subtype in the clinicopathologic diagnosing work [14]. Nevertheless, when tumor specimens contain more necrosis or mucus tissue, grading TSP is very difficult and it is meaningful to seek a new marker for assessing CMS4 subtype. As a member of TGF-β superfamily, whether Nodal expression has any relationship with TSP and thus can be used as a marker for CMS4 subtype? The present study also aimed to answer this question.

MATERIALS AND METHODS

Patients and Specimens

Tissue samples were obtained from the department of pathology of Guangzhou First People’s hospital. A total of 305 lesions were collected in this study between June 2017 and March 2018, including 18 juvenile polyps (JPs), 22 hyperplastic polyps (HPs), 22 inflammatory polyps (IPs), 24 sessile serrated adenoma/polyps (SSA/Ps), 30 tubular adenomas (TAs), 28 high-grade intraepithelial neoplasms (HGINs), 143 primary CRCs and 18 metastatic CRCs (pulmonary and liver metastases). Besides, a total number of 20 normal colon tissues were collected and used as control. All the CRC patients had undergone surgical operation and none of them had received radiotherapy or chemotherapy before surgery. Tumor type and grade were evaluated according to the 2016 World Health Organization (WHO) classification system. The pathological tumor stage was defined according to the seventh edition of the tumor-node-metastasis (TNM) staging of the American Joint Cancer Committee (AJCC). Primary colon cancer was classified into left-sided (including descending colon and sigmoid) and right-side (including caecum, ascending and transverse colon) tumors.

Immunohistochemistry Staining

Formalin-fixed and paraffin-embedded samples were cut into 4-μm thickness, deparaffinized in xylene, washed and dehydrated with graded ethanol, followed by antigen retrieval using high-pressure method with EDTA 9.0. The slides were then pretreated with 3% H₂O₂ for 10 min to block endogenous peroxidase activity and washed by PBS for three times. Afterward, the tissues were incubated with mouse monoclonal anti-Nodal antibody (1:300 dilution; ab55676; Abcam) at 37°C in water bath kettle for 45 min, following a 20 min incubation with biotin-linked secondary antibody (1:1000 dilution; ab47844; Abcam) at 37°C according to the manufacturer’s instructions. Then the sections were stained in DAB (diaminobenzidine tetrahydrochloride, Dako) solution and counterstained with hematoxylin for 1 min. Slides were then washed and dehydrated in graded ethanol, ultimately mounted under a cover slip. Each slide was observed under a light microscope (magnification, ×100) by two pathologists to obtain coincident results.

Cytoplasmic staining was considered Nodal-positive. The immunostaining of Nodal was scored according to positive cell rate and staining intensity. Two senior pathologists (XPW and HD) independently recorded the IHC results. The staining intensity was graded as follows: 0 score, no staining; 1 score, weak staining with light brown; 2 scoresintermediate staining; 3 scores, strongly stained with dark brown. The percentage of positive cells was divided into the following levels: 0 point for no cells positive; 1 point for <10% cells positive; 2 points for 10–50%, and 3 points for >50% cells positive, respectively. The staining index (SI) was calculated as (score for staining intensity) × (score for percentage of positive cells) [15, 16]. SI was divided into low group (total score ≤ 4.5) and high group (total score > 4.5) for further analysis.
Histopathological Scoring for TSP

The evaluation of TSP was conducted using microscopic analysis of 4-μm hematoxylin and eosin (H&E) stained sections from the most invasive part of CRC as previously described [17, 18]. All the tissues were fixed, dehydrated, paraffin-embedded and sectioned, followed by hematoxylin staining, washing under running water, hydrochloric acid alcohol differentiation, dehydration using graded ethanol and vitrification by dimethylbenzene. Then, the slides were covered with a glass slip. Using a ×5 objective, the invasive area with the desmoplastic stroma was selected. Subsequently, the fields where the stroma was infiltrated with small tumor nest were calculated using a ×10 objective, meanwhile ensuring that tumor cells were present at all four sides of the image (north–east–south–west) and excluding areas of necrosis or mucin. Two pathologists (XPW and HD) estimated all the samples respectively. The TSP value was divided into “stroma-high” (>50%) and “stroma-low” (≤50%) groups with a 50% cut-off value [14].

Statistical Analysis

Statistical analysis was carried out using SPSS 22.0 software (SPSS Inc, United States). The difference of Nodal expression among various types of colorectal lesions was compared using the Mann-Whitney U test. The Pearson Chi-square test was used for assessing the correlation between Nodal expression and clinicopathological parameters. Two categories logistic regression model was used for univariate and multivariate analysis to predict the odds ratio (OR) of individual factors for high TSP. Only variables with p value of less than 0.1 in the univariate model were included for further analysis in the multivariate logistic model. The ROC curve was plotted to evaluate the diagnostic value of Nodal in predicting high TSP. A p value of less than 0.05 was considered statistically significant.

RESULTS

Nodal Expression in Various Types of Colorectal Lesions and TSP in CRC Tissues

Results of Nodal expression in various types of colorectal lesions are summarized in Table 1. Nodal was expressed at low levels in normal colon tissue (SI = 0.75 ± 0.38), JP (SI = 0.89 ± 0.42), HP (SI = 0.86 ± 0.37), and IP (SI = 0.75 ± 0.31) (Figures 1A–D), and there were no statistically significant differences among the four groups (all p > 0.05). SSA/P (SI = 2.17 ± 1.09) showed a weak to moderate Nodal expression which was comparable with TA (SI = 2.40 ± 1.22) (Figure 1F) whereas higher than the former four types (all p < 0.0001). Nodal expression was significantly increased in HGIN (SI = 4.18 ± 1.81), primary tumor of CRC (SI = 4.97 ± 2.27) as well as metastases of CRC (SI = 4.61 ± 2.55) (Figures 1G–J) compared with other lesions (all p < 0.0001), however, no significant differences were found between the three groups. Representative high (>50%) and low (≤50%) TSP in CRC tissues were displayed in Figures 1K,L.

Relationship between Nodal Expression and Clinicopathologic Features in CRC Patients

We then investigated whether Nodal expression had relationship with other clinical features in CRC patients. In the CRC cells, Nodal was predominantly located in the cytoplasm and evaluated by SI criteria. As shown in Table 2, Nodal expression was significantly correlated with primary tumor site, AJCC stage, node stage, MMR status and TSP (all p < 0.05). Higher Nodal expression was prone to be found in left-sided colon cancer (compared with right-sided colon and rectum cancer, p = 0.044), advanced AJCC stage (stage III + IV compared with stage I + II, p = 0.001), lymphatic metastasis (positive compared with negative, p = 0.011), pMMR status (compared with mismatch repair-deficient (dMMR) status, p = 0.025) and high TSP (compared with low TSP, p < 0.001). There were 29 CRC cases (29/143, 20.3%) with high TSP (>50%), among which only five cases showed low expression of Nodal (5/29, 17.2%).

Risk Factor Analysis for High TSP

As Nodal expression significantly correlated with high TSP, we next conducted the univariate and multivariate logistic regression analysis to exploit the risk factors for high TSP. As shown in Table 3, pMMR status and high Nodal expression were two risk factors for high TSP in univariate model (all p < 0.1). However,
when it came into the multivariate logistic regression model, high Nodal expression was the only significant risk factor for high TSP (OR = 6.94, 95% confidence interval (CI) = 2.45–19.69, p < 0.001).

The Diagnostic Value of Nodal Expression in Predicting High TSP
As high Nodal expression was the only significant risk factor for high TSP and high TSP is thought to be a good marker for determining CMS4 subtype of CRC in the routine pathology, we then plotted the ROC curve to assess the diagnostic value of Nodal in predicting high TSP or determining CMS4 subtype of CRC. As shown in Figure 2, the outcome demonstrated that Nodal expression was able to efficiently distinguish high and low TSP (AUC = 0.773, 95% CI = 0.676–0.869, p < 0.001). The optimal cut-off point of Nodal expression was 5.50, at which point a sensitivity of 75.9% and a specificity of 67.5% were obtained.

DISCUSSION
Nodal is a member of the TGF-β superfamily, as effective to both embryological development and tumorigenesis. Growing researches have reported that Nodal is expressed in various tumors. Nodal plays an important role in angiogenesis, invasion and progression of cancer, as upregulation of Nodal caused a loss of E-cadherin and upregulated mesenchymal markers including N-cadherin, Twist1 and Vimentin, inducing EMT via the ERK pathway, thus played a promoting role [19], while suppression of Nodal expression reduced the clonogenicity, tumorigenesis and metastasis abilities of cancer cells [20, 21].

In the present study, we found that Nodal expression prominently increased in HGIN and CRC, whereas was at lower level in SSA/P and TA, and hardly expressed in normal colon tissue, JP, HP and IP. Previous research about Nodal expression in cutaneous melanocytic lesions showed that Nodal expression was significantly increased in malignant lesions including malignant melanoma, metastatic melanoma and melanoma in situ compared with those benign melanocytic lesions (no expression or low expression), indicating a role for Nodal in melanoma progression [15]. Nodal expression also increased in triple-negative breast cancer biopsies, whereas it was hardly detectable in benign breast lesions [22]. Based on our research and previously reported studies, we speculate that increased Nodal expression might also play an important role in tumorigenesis and progression of CRC, whereas needs further research to confirm it.

We further investigated the relationship between Nodal expression and clinicopathological characteristics in CRC, and
found that Nodal was related with the advanced node stage and AJCC stage in CRC, which was consistent with the fact that Nodal promotes tumor growth in CRC [23]. Guinney et al recently proposed four subtypes (CMS classifications) for CRC based on the consolidation of six different large genomic subtyping studies [10]. Among the four CMSs, CMS4 (mesenchymal, 23%) is mainly manifested as MSS status, being a SCNA-high and CIMP-negative phenotype, occurring at advanced stages, having a poorer prognosis, and exhibiting TGF-β activation, EMT activation, stromal infiltration, angiogenesis and matrix remodeling [10, 12, 24]. However, the CMSs are dependent on special genetic test and difficult to be detected by routine pathological methods. Recent studies have shown that TSP was an independent prognostic factor for CRC and association with poor overall survival, and can be deemed as a good marker to determine CMS4 subtype of CRC patients in routine pathological examination [18]. As a member of TGF-β superfamily, Nodal was presumed to be overexpressed and be a diagnostic marker in CMS4 CRC. In the present study, we found that high Nodal expression was the only independent risk factor for high TSP in CRC. ROC curve confirmed the diagnostic value of Nodal for predicting high TSP. As high TSP is thought to be a valuable marker to determine CMS4, we might also speculate that Nodal could be another reliable diagnostic index in CMS4 CRC, especially when tumor specimens contain much necrosis or mucus tissue, which makes grading TSP very difficult. Moreover, high Nodal expression correlated with pMMR status, left colon cancer and advanced stages, which were in accordance with the features of CMS4 CRC and further confirmed the above hypothesis.

Several limitations exist in our research. Accurate diagnosis of CMS relies on specialized genetic testing, which is too costly and discommodious to be introduced into routine pathology, so we just took TSP as an alternative “gold standard” for diagnosing CMS4. Besides, we inferred that Nodal might participate in the procedure of malignant transformation of CRC based on the finding that Nodal only overexpressed in HGIN and CRC instead of other benign lesions and normal colon tissues, however, the potential mechanism research such as which signaling pathway does Nodal work through was missing, which need further investigation in the future.

TABLE 2 | Clinicopathological characteristics of CRC patients based on Nodal expression.

| Characteristics                  | Nodal expression | r  | p-value |
|----------------------------------|------------------|----|---------|
| Number of cases (n, %)           | Low (<4.5)       |    |         |
| Age at diagnosis (years)         |                  |    |         |
| ≤61                              | 42 (66.0)        | 0.156 | 0.196 |
| >61                              | 33 (44.0)        |    |         |
| Gender                           | Male             |    |         |
| ≥61                              | 24 (32.0)        | 0.337 | 0.397 |
| Female                           | 51 (68.0)        |    |         |
| Primary tumor site               | Left colon       |    |         |
| ≥61                              | 20 (26.7)        | 0.044 |         |
| Right colon + Rectum             | Stage (7th AJCC) |    |         |
| I + II                           | 47 (62.7)        | 0.001 | 0.001  |
| III + IV                         | 28 (37.3)        |    |         |
| Tumor stage                      | T1 + T2          | 0.853 |         |
| ≥61                              | 13 (17.3)        |    |         |
| ≤61                              | 62 (82.7)        |    |         |
| Node stage                       | Positive         | 0.011 |         |
| ≥61                              | 51 (68.0)        |    |         |
| ≤61                              | 24 (32.0)        |    |         |
| Tumor histological grade         | Well + Moderately| 0.09 |         |
| ≥61                              | 61 (81.3)        |    |         |
| ≤61                              | 14 (18.7)        |    |         |
| Poorly + Mucinous                | KRAS mutation    | 0.857 |         |
| ≥61                              | 43 (57.3)        |    |         |
| ≤61                              | 32 (42.7)        |    |         |
| Yes                              | 43 (57.3)        |    |         |
| B-RAF mutation                   | No               | 0.189 |         |
| ≥61                              | 69 (92.0)        |    |         |
| ≤61                              | 6 (8.0)          |    |         |
| Yes                              | 32 (42.7)        |    |         |
| MMR status                       | pMMR             | 0.025 |         |
| ≤61                              | 55 (73.3)        |    |         |
| >61                              | 20 (26.7)        |    |         |
| Yes                              | 55 (73.3)        |    |         |
| TSP                              | ≤50%             | 0.001 |         |
| ≥61                              | 70 (93.3)        |    |         |
| ≤61                              | 5 (6.7)          |    |         |

r, contingency coefficient. The bold type indicates that the P value is statistically significant.

TABLE 3 | Logistic regression analysis of risk factors for high TSP.

| Factors                        | Univariate analysis | Multivariate analysis |
|--------------------------------|---------------------|----------------------|
|                                | OR (95% CI)         | p-value              |
|                                |                     |                      |
| Age at diagnosis (>61)         | 1.57 (0.69–3.59)    | 0.281                |
| Gender (female)                | 0.89 (0.38–2.06)    | 0.775                |
| Primary tumor site (left colon)| 1.47 (0.64–3.39)    | 0.368                |
| Stage (7th AJCC) (III + IV)    | 1.52 (0.67–3.47)    | 0.320                |
| Tumor stage (T3 + T4)          | 3.23 (0.71–14.61)   | 0.128                |
| Node stage (positive)          | 1.64 (0.72–3.73)    | 0.235                |
| Tumor histological grade (poorly + mucinous) | 0.98 (0.30–3.19) | 0.973 |
| KRAS mutation (yes)            | 0.67 (0.29–1.58)    | 0.363                |
| RAF mutation (yes)             | 1.33 (0.26–6.98)    | 0.733                |
| MMR status (pMMR)              | 0.25 (0.06–1.13)    | 0.071                |
| Nodal expression (≥4.5)        | 7.64 (2.71–21.5)    | <0.001               |

OR, odds ratio; 95% CI, 95% Confidence interval.
Only the meaningful factors (p < 0.1) in univariate analysis were brought into the multivariate analysis.

Pathology & Oncology Research 5
March 2021 | Volume 27 | Article 587029
Taken together, based on our research, Nodal might play a role in colorectal tumor progression and be used as a diagnostic marker to identify benign and malignant colorectal lesions under certain circumstances. Besides, Nodal might also be used as a marker for determining CMS4 subtype of CRC. We thus identified a potential driver of malignant transformation in colorectal lesions and a relatively simple and feasible method to determine the CMS4 subtype of CRC.

DATA AVAILABILITY STATEMENT

The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding author.

ETHICS STATEMENT

The studies involving human participants were reviewed and approved by the Research Ethics Committee of Guangzhou First People’s Hospital. The patients/participants provided their written informed consent to participate in this study.

AUTHOR CONTRIBUTIONS

XW, SL, HD, and HS designed and performed the research; XL and GL did immunohistochemical experiments; XL, GL, and YR collected and analyzed the data; XW, SL, and HC analyzed the results and wrote the manuscript. All authors read and approved the final manuscript.

FUNDING

This research was funded by General Guidance Project of Health Science and Technology of Guangzhou (20191A011010 to XW) and Natural Science Foundation of Guangdong Province (2017A030310337 to SL). The Science Foundation of Guangzhou First People's Hospital (M2019011 to XW).

CONFLICT OF INTEREST

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
REFERENCES

1. Vogelstein, B, Papadopoulos, N, Velculescu, VE, Zhou, S, Diaz, Lj, and Kinzler, KW. Cancer genome landscapes. Science (2013) 339:1546–58. doi:10.1126/science.1235122

2. Vogelstein, B, Fearon, ER, Hamilton, SR, Kern, SE, Preisinger, AC, Leppert, M, et al. Genetic alterations during colorectal-tumor development. N Engl J Med (1988) 319:525–32. doi:10.1056/NEJM19880913190901

3. Topczewska, JM, Postovit, LM, Margaryan, NV, Sam, A, Hess, AR, Wheaton, WW, et al. Embryonic and tumorigenic pathways converge via Nodal signaling: role in melanoma aggressiveness. Nat Med (2006) 12:925–32. doi:10.1038/nm1448

4. Postovit, LM, Margaryan, NV, Seftor, EA, Kirschmann, DA, Lipavsky, A, Wheaton, WW, et al. Human embryonic stem cell microenvironment suppresses the tumorigenic phenotype of aggressive cancer cells. Proc Natl Acad Sci USA (2008) 105:4329–34. doi:10.1073/pnas.0800467105

5. Lawrence, MG, Margaryan, NV, Loessner, D, Collins, A, Kerr, KM, Turner, M, et al. Reactivation of embryonic nodal signaling is associated with tumor progression and promotes the growth of prostate cancer cells. Prostate (2011) 71:1198–209. doi:10.1002/pros.21355

6. Strizzi, L, Hardy, KM, Margaryan, NV, Hillman, DW, Seftor, EA, Chen, B, et al. Potential for the embryonic morphogen Nodal as a prognostic and predictive biomarker in breast cancer. Breast Cancer Res (2012) 14:R75. doi:10.1186/bcr3185

7. Strizzi, L, Postovit, LM, Margaryan, NV, Lipavsky, A, Gadiot, J, Blank, C, et al. Nodal as a biomarker for melanoma progression and a new therapeutic target for clinical intervention. Expert Rev Dermatol (2009) 4:667–78. doi:10.1586/17469872.4.1.67

8. Gong, Y, Guo, Y, Hai, Y, Yang, H, Liu, Y, Yang, S, et al. Nodal promotes the self-renewal of human colon cancer stem cells via an autocrine manner through Smad2/3 signaling pathway. Biomed Res Int (2014) 2014:364134. doi:10.1155/2014/364134

9. Li, H, Jiang, Y, Pei, F, Li, L, Yan, R, Geng, X, et al. Aldehyde dehydrogenase 1 and nodal as significant prognostic markers in colorectal cancer. Pathol Oncol Res (2016) 22:121–7. doi:10.1007/s12253-015-9984-x

10. Guinney, J, Dienstmann, R, Wang, X, de Reynies, A, Schlicker, A, Soneson, C, et al. The consensus molecular subtypes of colorectal cancer. Nat Med (2015) 21:1350–6. doi:10.1038/nm.3967

11. Komor, MA, Bosch, LJ, Bounova, G, Bolijn, AS, Delis-yan, DP, Rausch, C, et al. Consensus molecular subtype classification of colorectal adenomas. J Pathol (2018) 246:266–76. doi:10.1002/path.5129

12. Inamura, K. Colorectal cancers: an update on their molecular pathology. Cancers (2018) 10:26. doi:10.3390/cancers1010026

13. Roepman, P, Schlicker, A, Taberner, J, Majewski, I, Tian, S, Moreno, V, et al. Colorectal cancer intrinsic subtypes predict chemotherapy benefit, deficient mismatch repair and epithelial-to-mesenchymal transition. Int J Cancer (2014) 134:552–62. doi:10.1002/ijc.28387

14. Roseweir, AK, McMillan, DC, Horgan, PG, Edwards, J. Colorectal cancer subtypes: translation to routine clinical pathology. Cancer Treat Rev (2017) 57: 1–7. doi:10.1016/j.ctrv.2017.04.002

15. Yu, L, Harms, PW, Pouryazdanparast, P, Kim, DS, Ma, L, Fullen, DR. Expression of the embryonic morphogen Nodal in cutaneous melanocytic lesions. Mod Pathol (2010) 23:1209–14. doi:10.1038/modpathol.2010.101

16. Chen, MH, Yip, GW, Tse, GM, Moriya, T, Lui, PC, Zin, ML, et al. Expression of basal keratins and vimentin in breast cancers of young women correlates with adverse pathologic parameters. Mod Pathol (2008) 21:1183–91. doi:10.1038/modpathol.2008.90

17. Mesker, WE, Jungeberg, JM, Szuhai, K, de Heer, P, Morreau, H, Tanke, HJ, et al. The carcinoma-stromal ratio of colon carcinoma is an independent factor for survival compared to lymph node status and tumor stage. Cell Oncol (2007) 29:387–98. doi:10.1155/2007/175276

18. Park, JH, Richards, CH, McMillan, DC, Horgan, PG, Roxburgh, CS. The relationship between tumour stroma percentage, the tumour microenvironment and survival in patients with primary operable colorectal cancer. Ann Oncol (2014) 25:644–51. doi:10.1093/annonc/mdt593

19. Quail, DF, Zhang, G, Findlay, SD, Hess, DA, Postovit, LM. Nodal promotes invasive phenotypes via a mitogen-activated protein kinase-dependent pathway. Oncogene (2014) 33:461–73. doi:10.1038/onc.2012.608

20. Quail, DF, Zhang, G, Walsh, LA, Siegers, GM, Dieters-Castator, DZ, Findlay, SD, et al. Embryonic morphogen nodal promotes breast cancer growth and progression. PLoS One (2012) 7:e48237. doi:10.1371/journal.pone.0048237

21. Quail, DF, Walsh, LA, Zhang, G, Findlay, SD, Moreno, J, Fung, L, et al. Embryonic protein nodal promotes breast cancer vascularization. Cancer Res (2012) 72:3851–63. doi:10.1158/0008-5472.CAN-11-3951

22. Kissamrger, G, Strizzi, L, Margaryan, NV, Gilgur, A, Hyser, M, Atkinson, J, et al. Nodal signaling promotes a tumorigenic phenotype in human breast cancer. Semin Cancer Biol (2014) 24:90–40. doi:10.1016/j.semcancer.2011.07.007

23. Li, Z, Zhang, J, Zhou, J, Lu, L, Wang, H, Zhang, G, et al. Nodal facilitates differentiation of fibroblasts to cancer-associated fibroblasts that support tumor growth in melanoma and colorectal cancer. Cells (2019) 8:538. doi:10.3390/cells08050538

24. Ubink, I, van Eden, WJ, Snaebjornsson, P, Kok, N, van Kuik, J, van Kuik, J, van Grevenstein, W, et al. Histopathological and molecular classification of colorectal cancer and corresponding peritoneal metastases. Br J Surg (2018) 105:e204–11. doi:10.1002/bjs.10788

Copyright © 2021 Wang, Liu, Gao, Li, Rong, Liu, Du and Shen. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.